亚太药业“易主”最新进展 协议转让已获深交所合规性确认

Core Viewpoint - Zhejiang Apac Pharmaceutical Co., Ltd. has made significant progress in the transfer of control, with the Shenzhen Stock Exchange confirming the share transfer agreement, indicating a successful transition of control to Xinghao Holdings and its actual controller, Mr. Qiu Zhongxun [1][2] Group 1: Control Transfer Details - The share transfer involves a 14.61% stake at a price of 8.26 yuan per share, totaling 900 million yuan, marking a significant change in the company's control [1] - The new actual controller, Mr. Qiu Zhongxun, has over 20 years of experience in the pharmaceutical industry and is the chairman of Yaodou Technology, a leading digital pharmaceutical platform [2] Group 2: Financial and Strategic Implications - The control transfer includes a plan for a private placement of up to 700 million yuan, aimed at funding new drug research and development projects [2] - The confidence shown by the new controller through the private placement is expected to ensure the long-term stability and sustainable development of the company [2] Group 3: Future Development and Innovation - Apac Pharmaceutical is committed to transforming into an innovative drug company, focusing on a combination of generic and innovative drug development [4] - The company has 114 approved drug formulations, with 19 products having passed consistency evaluations, and is expected to benefit from the national drug centralized procurement [4][5] - The collaboration with Yaodou Technology is anticipated to enhance the commercialization of innovative products, improving the efficiency of research outcomes and providing a competitive edge in the market [5]